SOUTH SAN FRANCISCO, Calif., March 12, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that it will present at the Jefferies 2015 Antibiotic Summit in New York, New York. Kenneth Hillan, Chief Executive Officer, is scheduled to present on Wednesday, March 18th at 3:10 p.m. Eastern Time.
About Achaogen
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Through the Special Protocol Assessment procedure, the U.S. Food and Drug Administration has agreed that the design and planned analyses of Achaogen’s Phase 3 CARE trial adequately address objectives in support of a New Drug Application. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections.
CONTACT: Candice Knoll Blueprint Life Science Group 415.375.3340 Ext. 105 cknoll@bplifescience.com
Help employers find you! Check out all the jobs and post your resume.
